Ecallantide for the Treatment of Hereditary Angiodema in Adults

Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of C1 esterase inhibitor (C1-INH). HAE has traditionally been divided into two subtypes. Unique among the inherited deficiencies of the complement system, HAE Types I and II are inherited as an autosomal dominant disorder. The generation of an HAE attack is caused by the depletion and/or consumption of C1-inhibitor manifested as subcutaneous or submucosal edema of the upper airway, face, extremities, or gastrointestinal tract mediated by bradykinin. Attacks can be severe and potentially life-threatening, particularly with laryngeal involvement and treatment of acute attacks in the United States has been severely limited. In December 2009 the FDA approved ecallantide for the treatment of acute HAE attacks. Ecallantide is a small recombinant protein acting as a potent, specific and reversible inhibitor of plasma kallikrein which binds to plasma kallikrein blocking its binding site, directly inhibiting the conversion of high molecular weight kininogen to bradykinin. Administered subcutaneously, ecallantide was demonstrated in two clinical trials, EDEMA3 and EDEMA4, to decrease the length and severity of acute HAE attacks. Although there is a small risk for anaphylaxis, which limits home administration, ecallantide is a novel, safe, effective and alternative treatment for acute HAE attacks.

[1]  J. Bernstein,et al.  Current and Emerging Management Options for Hereditary Angioedema in the US , 2012, Drugs.

[2]  W. Lumry,et al.  EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  F. Hsu,et al.  Results of a 2-Stage, Phase 3 Pivotal Trial, EDEMA3®: A Study of Subcutaneous DX-88 (Ecallantide), a Plasma Kallikrein Inhibitor, in Patients with Hereditary Angioedema (HAE) , 2008 .

[4]  A. Sheffer,et al.  Hereditary angioedema: Safety of long-term stanozolol therapy. , 2007, The Journal of allergy and clinical immunology.

[5]  Lynda Schneider,et al.  Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. , 2007, The Journal of allergy and clinical immunology.

[6]  D. Pompliano,et al.  Nat. Rev. Drug Disc. , 2007 .

[7]  A. Davis.  Mechanism of angioedema in first complement component inhibitor deficiency. , 2006, Immunology and allergy clinics of North America.

[8]  J. Levy,et al.  The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema , 2006, Expert opinion on investigational drugs.

[9]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[10]  R. Ladner,et al.  Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein , 1996, Molecular Diversity.

[11]  K. Whaley,et al.  Regional assignment of the human C1-inhibitor gene to 11q11–q13.1 , 1990, Human Genetics.

[12]  W. Tremaine,et al.  Hereditary angioedema: a broad review for clinicians. , 2001, Archives of internal medicine.

[13]  J. Weiler,et al.  A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. , 2001, Clinical immunology.

[14]  S. Choquet,et al.  Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. , 2000, The Journal of allergy and clinical immunology.

[15]  K. Binkley,et al.  Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. , 2000, The Journal of allergy and clinical immunology.

[16]  K. Bork,et al.  Hereditary angioedema with normal C1-inhibitor activity in women , 2000, The Lancet.

[17]  B. Zuraw,et al.  Detection of C1 inhibitor mutations in patients with hereditary angioedema. , 2000, The Journal of allergy and clinical immunology.

[18]  N. Thielens,et al.  Structural and functional studies on C1r and C1s: new insights into the mechanisms involved in C1 activity and assembly. , 1998, Immunobiology.

[19]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[20]  A. Schmaier,et al.  Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. , 1997, Blood.

[21]  P. Mannucci,et al.  Activation of the coagulation cascade in C1-inhibitor deficiencies. , 1997, Blood.

[22]  R. Ladner,et al.  Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. , 1996, Biochemistry.

[23]  A. Davis.  C1 inhibitor and hereditary angioneurotic edema. , 1988, Annual review of immunology.

[24]  R. Huber,et al.  Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. , 1986, Biochemistry.

[25]  R. Colman,et al.  Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. , 1982, The Journal of clinical investigation.

[26]  J. Atkinson,et al.  Hereditary angioedema: the clinical syndrome and its management. , 1976, Annals of internal medicine.

[27]  V. Donaldson.  Therapy of "the neurotic edema". , 1972, The New England journal of medicine.

[28]  F. Rosen,et al.  The "neurotic edema" (hereditary angioedema). , 1969, The New England journal of medicine.

[29]  Mcgarry Al.  TREATMENT OF NARCOTIC ADDICTION. , 1965 .

[30]  A. Mcgarry.  THE NEUROTIC EDEMA. , 1965, The New England journal of medicine.

[31]  R. R. Evans,et al.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. , 1963, The American journal of medicine.